A single nucleotide polymorphism (SNP) in the TRAILR-1 gene is associated with the clinical response to IFN-β therapy in patients with multiple sclerosis (MS), according to a study conducted in a Spanish cohort. TRAILR-1 encodes a receptor for TRAIL, a proapoptotic cytokine that has been implicated in MS pathogenesis. The CC genotype of the rs20576 SNP, which results in a Glu228Ala substitution in TRAILR-1, was found to correlate with an enhanced response to IFN-β, and might be a useful biomarker to predict the outcome of this treatment.
ORIGINAL RESEARCH PAPER
López-Gómez, C. et al. Candidate gene study of TRAIL and TRAIL Receptors: association with response to interferon beta therapy in multiple sclerosis patients. PLoS ONE 8, e62540 (2013)
Rights and permissions
About this article
Cite this article
On the TRAIL of IFN-β response. Nat Rev Neurol 9, 299 (2013). https://doi.org/10.1038/nrneurol.2013.99
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.99